Last week, Pfizer submitted a request to the Food & Drug Administration (FDA) for emergency authorization of the COVID-19 vaccine for children ages 5 to 11. Ahead of this request, the FDA’s independent vaccine advisory committee, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), announced it will hold a meeting on October 26 about emergency use authorization for vaccines for 5- to 11-year-olds.
The VRBPAC announced two additional meetings in October to discuss the use of booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines. The Committee will also hear presentations and discuss the available data on the use of a booster of a vaccine other than the one used for an individual’s initial COVID-19 vaccine series, also known as a “mix and match” booster.
The schedule for the advisory committee meetings is below:
On Oct. 14, the VRBPAC will discuss the emergency authorization of the Moderna COVID-19 vaccine booster for individuals 18 years of age and older.
On Oct. 15, the VRBPAC will discuss the emergency authorization of Johnson and Johnson’s Janssen COVID-19 vaccine booster for individuals 18 years of age and older. Additionally, the committee will hear a presentation from the National Institute of Health’s National Institute of Allergy and Infectious Diseases on mix and match booster doses.
On Oct. 26, the VRBPAC will discuss the emergency authorization of vaccines for children aged 5 to 11.